The European Commission has decided to approve the drug Vyepti (eptinezumab) for the preventive treatment of migraines in adults who have at least four migraine attacks per month.
The announcement was expected, as the European Medicines Agency’s Expert Committee on Medicinal Products for Human Use, CHMP, issued a favourable statement in November l...
Lundbeck behind the first EU-approved intravenous migraine treatment
A preventive, intravenous treatment for migraines has been approved in the EU for the first time.
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration